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INTRODUCTION
The concept that human viral hepatitis was caused by no more than two etiologic
agents stemmed from early volunteer studies in which two epidemiologically distinct
types ofhepatitis were transmitted to humans (1). These experimentally transmitted
diseases closely resembled two forms ofnaturally occurring viral hepatitis that could
be distinguished on epidemiologic grounds. One form was highly infectious, spread by
the fecal oral route, with a relatively short incubation period of 2 to 6 weeks ("in-
fectious hepatitis" or hepatitis type A); the other usually occurred following
parenteral inoculations and was characterized by a long incubation period (ap-
proximately 6 weeks to 6 months), little, ifany, person-to-person spread, and lack of
association with epidemics except where multiple inoculations with the same
contaminated syringe had occurred ("serum hepatitis" or hepatitis type B).
Early epidemiologic studies failed to provide evidence for more than two viral hep-
atitis agents (1). However, the possibility of other human hepatitis viruses was sug-
gested by the finding of hepatitis cases with an incubation period intermediate
between that ofhepatitis A and B viruses (2). More recently, multiple cases ofhepa-
titis occurring among illicit drug users suggested that three or more etiologic agents
might exist (2).
With the discovery of hepatitis B surface antigen (HB,Ag) and its association
specifically with type B hepatitis (3, 4), a method to reevaluate accepted beliefs about
type B hepatitis became available. Some surprises emerged. Among these was the
finding that a significant proportion of "sporadic" hepatitis not acquired by demon-
strable percutaneous exposure was, in reality, associated with HB,Ag. Furthermore,
epidemiologic surveys for HB,Ag and antibody to HB,Ag (anti-HB,) provided
serologic evidence of exposure to hepatitis B virus (HBV) among a proportion of
affected individuals whose mode of infection was incompatible with the concept of
strictly percutaneous spread of the virus (5). Even more interesting was the finding
that a significant proportion of transfusion-associated hepatitis could not be related
serologically to hepatitis B virus infection (6, 7). It was thought that such "non-B"
hepatitis was undiagnosed type B infection or, more likely, percutaneously transmit-
ted type A hepatitis. However, epidemiologic studies as far back as 1962 strongly
suggested that the latter was not the case: The incubation period of transfusion-
associated hepatitis defined a unimodal curve with its peak 45 to 49 days after ex-
posure, strongly suggesting that short incubation period type A hepatitis was not an
important cause ofillness in blood recipients (8). Similar conclusions were reached in
a recent study oftransfusion-associated hepatitis (9).
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Nomenclature
The designation of "infectious hepatitis" and "serum hepatitis" for the two
recognized forms of viral hepatitis imbued them with erroneous epidemiologic
qualities. For this reason, the less connotative names "hepatitis, type A" and "hepa-
titis, type B" (10, 11) were revived, but the concept of two and only two types of
hepatitis survived, and all hepatitis not identifiable as type B was defined by exclusion
as type A. To avoid such as assumption, Blumberg suggested that viral hepatitis
should be classified as being Australia antigen (HB,Ag) positive or negative (12).
Currently available tests for markers of hepatitis B virus infection (13) are
sufficiently sensitive to detect almost all hepatitis B virus infections; thus it seems
reasonable, in the absence of definitive evidence for hepatitis A virus infection, to
modify Blumberg's proposal to classify patients with any serologic evidence of
primary exposure to hepatitis B antigens as type B and those with no serologic evi-
denceofexposure as type non-B.
The development of sensitive tests for indicators of hepatitis A virus infection
(hepatitis A antigen and antibody) now makes it possible to divide non-B hepatitis
into type A hepatitis and non-A, non-B hepatitis (14-20). Although the term "type C
hepatitis" has been suggested for the latter disease (9, 21), there is evidence that non-
A, non-B hepatitis may be caused by more than one agent (see below), and we believe
it wiser, therefore, to use the less mellifluous but more accurate designation type
non-A, non-B hepatitis. The term type C hepatitis should be reserved until type non-
A, non-B hepatitis can be defined serologically.
The RoleofIdentifiable Agents in Non-A, Non-B Hepatitis
Both cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are known to cause
hepatitis as part ofthe generalized infection characteristicoftheseherpesviruses (22,
23). Epstein-Barr virus appears to play a minor role in type non-B hepatitis, as
judged by the infrequency ofserologic evidence of associated infection with this virus
(6, 24-28). The role of CMV in type non-B hepatitis is more difficult to evaluate be-
cause of the presence of multiple, partially related serotypes of the virus and a
demonstration of variation in anti-CMV antibody levels in normal individuals
followed longitudinally (29, 30). Convincing evidence for an etiologic role of CMV in
some cases of hepatitis associated with transfusion or immunosuppression has been
presented (23, 31, 32), but most cases oftype non-B hepatitis lack such evidence, and
serologic evidence of recent CMV infection can be found as frequently in transfused
patients who develop hepatitis as in those who do not (6, 9, 33, 34). Thus, the im-
portance of CMV in the etiology of type non-B transfusion-associated hepatitis is
difficult to evaluate but is probably not great.
Epidemiology
Type non-A, non-B hepatitis was first identified in transfused patients and was dis-
tinguished from type A hepatitis on both epidemiologic and serologic grounds (9,
24-26, 35, 36). Although an etiologic agent could not be ascribed to over halfof the
cases oftransfusion-associated hepatitis detected in early studies (6), it was assumed
that many of these were caused by HBV but could not be diagnosed because of the
relative insensitivity of tests for HB.Ag and anti-HB, available at that time.
However, few additional HBV infections were identified when more sensitive
serologic tests were applied to serial samples obtained from these longitudinally
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followed patients (Purcell, R. H., unpublished). Furthermore, the combined impact
of HB,Ag-screening programs and the curtailment of the use of commercially
derived blood has resulted in a smaller proportion oftransfusion-associated hepatitis
caused by HBV. At present, as much as 90% of such hepatitis appears to be type
non-A, non-B (26, 37, 38). Hepatitis A virus, serologically related to the MS-l strain
of virus described by Krugman et al. (39), appears to be responsible for most epi-
sodes of epidemic hepatitis, including water-borne and food-borne outbreaks, explo-
sive epidemics occurring within institutions and families, shellfish-associated hepa-
titis, and hepatitis among handlers of nonhuman primates. The distribution of this
virus is probably worldwide. In contrast, non-B "sporadic" hepatitis not associated
with the epidemiologic settings described above appears to be caused by both HAV
and non-A, non-B agents.
Although data are as yet limited, type non-A, non-B hepatitis has been detected
throughout the world, including the United States (25, 40), Japan (Moritsugu, Y.,
personal communication), Costa Rica (41), and, possibly, Australia (Gust, I. D., et
al., in preparation), Great Britain (42) and Germany (43). Within the United States,
type non-A, non-B hepatitis has been detected wherever it has been sought; in one
study, over halfof the non-B sporadic hepatitis observed was found to be type non-A,
non-B (Mosely, J. W., et al., in preparation). It therefore seems likely that a sig-
nificant but undetermined proportion of the greater than 50,000 cases of viral hepa-
titis reported annually in the United States is type non-A, non-B hepatitis.
As with type B hepatitis, type non-A, non-B hepatitis occurs significantly more
frequently following transfusion ofcommercially derived blood than following receipt
of blood derived from volunteer sources. Thus, type non-A, non-B disease (or non-B
hepatitis presumed to be non-A) has been found to occur five to ten times more
frequently following transfusion of the former than following transfusion of the latter
(9, 37, 38). Despite increasing use of voluntarily donated blood and application of the
most sensitive techniques for screening blood for HB,Ag, type non-A, non-B hepatitis
is still occurring at a rate of three to six cases/1000 units of blood transfused (26, 37,
38).
The epidemiology of type non-A, non-B hepatitis resembles more closely that of
type B hepatitis than that of type A disease. Thus, type non-A, non-B hepatitis oc-
curs commonly following parenteral exposure to blood or illicit drugs, appears to be
endemic in many populations but is not readily spread from person to person, occurs
more commonly among those of low socioeconomic status such as commercial blood
donors, and, on the basis of the observed rate of disease following transfusion, must
result in an infectious carrier state.
Clinical Characteristics
The average non-A, non-B hepatitis case appears to differ clinically in several
small but significant ways from type B illness, but, as with the latter, the clinical
expression of the former is so variable that a diagnosis on clinical grounds alone can-
not be made reliably in individual cases.
On the basis oflimited studies, the average incubation period oftype non-A, non-B
hepatitis appears to be 6 to 7 weeks shorter than that of type B hepatitis (24-26), but
the extreme variability of the incubation period makes its determination of little
value for diagnosis (Table 1). Interestingly, these incubation periods for serologically
confirmed type non-A, non-B and type B hepatitis are very similar to those reported
by Mosely (36) for hepatitis occurring after administration of whole blood only (9.9
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TABLE 1
Transfusion-Associated Hepatitis: Incubation Period
Typeof Mean incubation
hepatitis Number period (weeks)" Range
Bb 18 14.4 4-25
Non-A, non-B 22 7.3 2-22
From transfusion to first elevated SGPT value.
HBsAg positive.
weeks) and blood products only (14.6 weeks) during the period 1961-1965, prior to
widespread testing for HBsAg, and provide additional suggestive evidence that over
half of the transfusion-associated hepatitis reported at that time was not caused by
HBV (6). Others have found less difference in incubation periods between type B
hepatitis and non-B cases (9, 37, 38).
Type B hepatitis is more acutely severe than type non-A, non-B disease, resulting
in a higher proportion of icteric cases and a higher mean maximum SGPT value
(24-26) (Table 2). Again, the range of maximum SGPT values is too broad to be of
value for diagnosis. A greater severity of type B hepatitis when compared to non-B
disease has also been noted in previous studies (9, 37, 38).
Although type non-A, non-B hepatitis is associated with less severe acute illness
than type B disease, asjudged by frequency ofjaundice and magnitude ofSGPT ele-
vations, the long-term prognosis for the two diseases may be similar. Thus, elevation
of transaminase values persisting for 6 or more months has been observed more
frequently following non-A, non-B disease than following type B hepatitis (Table 3).
Others have reported similar results (37). Transaminase elevations have been docu-
mented for several years in some patients. Three such patients at the NIH
underwent liver biopsy; two had histopathologic changes in the liver compatible with
chronic active hepatitis, and the other was diagnosed as having chronic persistent
hepatitis (44; Alter, H. J., et al., unpublished). Thus, chronic non-A, non-B hepatitis
is not necessarily a benign infection and may be the cause of a significant proportion
ofchronic hepatitis notidentifiable as type B disease.
An interesting feature of some cases of chronic non-A, non-B hepatitis is the
episodic nature of transaminase elevations; periods of transaminase elevation al-
ternate with periods of normal or near normal transaminase activity. Such a cyclic
TABLE 2
Transfusion-Associated Hepatitis: Severity
Typeof Number Mean maximum
hepatitis Number icteric SGPT value Range
B 19 12 (63%) 768 157-2050
Non-A, non-B 22 6 (27%) 395 120-1476
TABLE 3
Transfusion-Associated Hepatitis: Duration of Illness
Number with
Typeof SGPT elevation
hepatitis Number persisting > 6 months
B 19 3 (6%)
Non-A, non-B 21 7 (33%)
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pattern of hepatitis activity appears to occur more frequently in the patient with
chronic (or persistent) non-A, non-B hepatitis than in the individual chronically ill
with type B disease and care must be exercised that these repeating episodes ofhepa-
titis are not interpreted as representing separate and distinct bouts ofacute hepatitis.
Attempts to Identify the Agent (orAgents)ofNon-A, Non-B Hepatitis
Several approaches to the identification of agents or antigens associated with non-
A, non-B hepatitis are being pursued. Among these is a search for an antigen
analagous to hepatitis A and B antigens but specific for non-A, non-B hepatitis. In
these experiments, acute phase serum and plasma from patients with non-A, non-B
hepatitis are being examined by solid phase radioimmunoassay and immune electron
microscopy techniques for unique antigens. In addition, chimpanzees and other
species of nonhuman primates are being inoculated with acute phase serum or
plasma from patients with non-A, non-B hepatitis. To date, noneofthese approaches
has yielded unequivocally positive results, but the search continues for the agent of
non-A, non-B hepatitis.
Failure to demonstrate non-A, non-B hepatitis in chimpanzees may be explained
by an insusceptibility of this species to thevirus; susceptibility resulting in inapparent
(undetected) infection; or presence of immunity resulting from a prior naturally ac-
quired infection. However, the failure, to date, to detect an antigen specific for type
non-A, non-B hepatitis or to transmit an agent to chimpanzees, a species known to be
susceptible to both hepatitis A and B viruses, also suggests that the agent of this
disease may be present in relatively low titer in acute phase serum or that it is rela-
tively labile and destroyed by freezing, storage at -70°C and/or subsequent thaw-
ing. Alternatively, the agent may be cell associated and therefore inseparably bound
to one of the cellular components ofblood. Such cell association is a common charac-
teristic of many herpesviruses such as CMV and varicella zoster virus (45). That one
or more of these latter predictions is correct is suggested by the observation that
non-A, non-B hepatitis occurs infrequently, ifat all, following parenteral administra-
tion ofprocessed blood products such as clotting factors, a finding anticipated by the
epidemiologic study of Mosely (36). However, additional studies must be carried out
to determine if the largely anicteric disease associated with non-A, non-B hepatitis
has been overlooked in previous studies ofhepatitis following administration ofthese
components.
One transmissible agent that causes hepatitis in marmosets has been proposed as a
candidate for non-A, non-B hepatitis virus. In 1967, Deinhardt et al. reported the
isolation and serial transmission in marmosets of an agent thought to be hepatitis A
virus (46). Parks and Melnick subsequently cast doubt on the authenicity of this
agent, named the GB agent after the surgeon from whom it was isolated, and sug-
gested that this virus was a contaminant, possibly a latent virus of marmosets, and
not related to human hepatitis (47, 48). Subsequent studies by Deinhardt and his
group resulted in the transmission ofa bona fide hepatitis A virus, the MS-I strain, to
marmosets and the demonstration that this hepatitis A virus was distinct from the
GB agent (49). Paired serum samples from the surgeon from whom the GB agent was
recovered have been studied for serologic evidence ofhepatitis A and B virus infec-
tion; evidence for recent infection with either of these viruses could not be detected
(Dienstag, J. L., and Deinhardt, F., unpublished). Therefore, GB may have had non-
A, non-B hepatitis. Deinhardt has suggested that the GB agent is, in fact, a non-A,
non-B hepatitis agent (21), but the inability to perform serologic tests with the GB
agent (other than cross-challenge experiments in marmosets) has made it impossible
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to determine the significance, if any, of the GB agent in the etiology ofnon-A, non-B
hepatitis.
Evidencefor More than One Non-A, Non-B Hepatitis Agent
Mosley recently reported the documentation ofthree separate boutsofhepatitis in
six patients and four distinct bouts in an additional five patients longitudinally
followed in a study of hepatitis in Los Angeles and cited other reports of multiple
bouts ofhepatitis (2). Serologic analysis ofthese multiple bouts ofhepatitis (Mosely,
J. W., et al., submitted for publication) has revealed that as many as two and three
separate bouts ofhepatitis in one individual were not identifiable as types A or B and
were therefore probably type non-A, non-B hepatitis. These bouts did not appear to
be instances of recurrent chronic type non-A, non-B hepatitis, as described above, for
liver biopsy revealed each of them to be associated with histopathologic evidence of
acute hepatitis. Furthermore, there was no serologic evidence that any ofthese bouts
ofhepatitis were caused by EBV or CMV. Thus, there is seroepidemiologic evidence
that two or more agents may be responsible for non-A, non-B hepatitis, but more de-
finitive studies must await the discovery of serologic markers for non-A, non-B
disease.
Prevention ofType Non-A, Non-B Hepatitis
Numerous studies of the efficacy of immune serum globulin for prevention of
transfusion-associated hepatitis have yielded equivocal results (50). Only one study
to date has carefully segregated such hepatitis into type B and non-B (presumably
non-A, non-B) (38). In this study immune serum globulin afforded minimal, if any,
protection in preventing non-A, non-B hepatitis when compared to an albumin
placebo.
At present the most effective means of preventing transfusion-associated non-A,
non-B hepatitis is the substitution of blood derived from volunteer sources for com-
mercial blood. The exclusive use ofvolunteer blood has been shown to reduce mark-
edly (but not eliminate) the incidence ofboth type B hepatitis and type non-A, non-B
disease (37, 38, 44).
CONCLUSIONS
There is evidence that at least one additional agent is etiologically responsible for
human viral hepatitis; hepatitis caused by this agent (or agents) is unrelated to hepa-
titis caused by hepatitis A or B viruses. The epidemiology ofsuch non-A, non-B hepa-
titis resembles that oftype B hepatitis more than that oftype A disease. Type non-A,
non-B hepatitis can progress to a chronic state. Attempts to identify an antigen
specific for non-A, non-B hepatitis or to transmit the disease to nonhuman primates
have, to date, been unsuccessful. Such lack of success may reflect the lack ofappro-
priate reagents or may suggest that the agent is cell associated, labile, or present in
relatively low titer. The role ofimmune serum globulin in the prevention or modifica-
tion of type non-A, non-B hepatitis is poorly defined; at present, the most effective
means ofdiminishing the frequency of transfusion-associated non-A, non-B hepatitis
is the useofblood derived solely from volunteer sources.
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